MarketLens
Sign Up

Is BioVie's Bezisterim Poised for a Breakthrough in Neurodegenerative Diseases

4 months ago
SHARE THIS ON:

Is BioVie's Bezisterim Poised for a Breakthrough in Neurodegenerative Diseases

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 weeks ago

Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

Biogen's growth products, including Skyclarys and Zurzuvae, now outpace its legacy multiple sclerosis portfolio, shifting the revenue mix. The transition reduces reliance on declining MS drugs but con...
Stock News•2 months ago

Renew Biotechnologies Publishes Peer-Reviewed Research Advancing Cell-Type-Associated Biomarkers of Neurodegeneration

Renew Biotechnologies published peer-reviewed research in Frontiers in Neurology advancing cell-type-associated biomarkers for neurodegeneration, potentially strengthening its diagnostic platform and ...
Stock News•2 months ago

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

BioVie's bezisterim met Phase 2 SUNRISE-PD endpoints, showing statistically significant motor and non-motor symptom improvements versus placebo in early Parkinson's disease, plus reduced neurodegenera...

Breaking News

View All →

Top Headlines

View More →
Stock News•1 hour ago

Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

Stock News•1 hour ago

Why the Market Dipped But Microsoft (MSFT) Gained Today

Stock News•1 hour ago

Nvidia (NVDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Stock News•1 hour ago

Tesla (TSLA) Declines More Than Market: Some Information for Investors

Stock News•1 hour ago

Amazon Will Be The Final Winner Of The AI Race With Anthropic's Help